ClinicalTrials.gg
DrugBiological

LY3022855 clinical trials

Also written LY3022855.

studies test it
4
open now
0
in phase 3
0
first study started
2011

How each study uses LY3022855 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

IMC-CS4
3

Development codes

LY3022855
4

Studies by the year they started

4 studies that test it; most in 2011 (1)

Studies that test LY3022855, by start year
YearStudies
20111
20151
20171
20181

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 2 · Other 2

Eli Lilly and Company (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Dana-Farber Cancer Institute (1)

Studies

Open first, then newest update. How each study uses LY3022855 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Given beside what is tested · 1 — LY3022855 is usual care or a partner of the new treatment